A breakthrough CRISPR therapy, VERVE-102, shows promise for lifelong cholesterol control with a single dose, achieving up to ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780 ... the majority of patients with atherosclerotic disease today do not reach their LDL-cholesterol goals, despite ...

Pfizer is offering research grants to support projects advancing knowledge of the importance of PCSK9 in cardiovascular disease, the target of its late-stage drug candidate bococizumab.

Despite the evidence now linking the PCSK9 variant to metastatic disease, Tavazoie clarifies that patients with this variant should not be alarmed. The data suggests that patients with the variant ...

Patients don’t consistently stay on their PCSK9 doses. So a one-time treatment for life, such as Verve’s, is intriguing for fighting an illness such as cardiovascular disease, whose risk rises ...

PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A pharmacist-managed cholesterol service can optimize PCSK9 inhibitor access, use and effectiveness.

Future studies should address implementation science, including the immediate coadministration of a PCSK9 inhibitor with a statin for high-risk cardiovascular disease patients who require greater ...

These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as ...

Verve Therapeutics (VERV) announced initial data from the Heart-2 Phase 1b clinical trial of VERVE-102. The Heart-2 Phase 1b clinical trial is ...